Trial intelligence / Profile preview

3 vs 7 Days Antibiotic Prophylaxis for HoLEP

NCT07209150Phase 3Not yet recruiting

Sponsor: The Ohio State University
Start: Jan 2026
Primary completion: Dec 2027

Overview

Phase 3, randomised, open-label trial in urinary tract infection (UTI), pyelonephritis and sepsis (2 arms), sponsored by The Ohio State University. Primary endpoint: Infectious complications. Planned start Jan 2026; status: not yet recruiting.

Conditions

urinary tract infection (UTI)pyelonephritissepsis

Beyond the preview

Go deeper on NCT07209150.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT07209150.